Zogenix, Inc.  

(Public, NASDAQ:ZGNX)   Watch this stock  
Find more results for ZGNX
1.65
+0.03 (1.85%)
After Hours: 1.70 +0.05 (3.03%)
Apr 21, 6:32PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.60 - 1.66
52 week 1.07 - 3.10
Open 1.60
Vol / Avg. 1.56M/4.13M
Mkt cap 248.45M
P/E 23.01
Div/yield     -
EPS 0.07
Shares 153.36M
Beta 2.31
Inst. own 74%
May 6, 2015
Q1 2015 Zogenix Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 10, 2015
Q4 2014 Zogenix Inc Earnings Call - Webcast
Mar 10, 2015
Q4 2014 Zogenix Inc Earnings Release
Feb 11, 2015
Zogenix, Inc. at Leerink Swann Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -137.73% 21.19%
Operating margin -181.64% -52.54%
EBITD margin - -240.69%
Return on average assets -53.13% 5.45%
Return on average equity -145.92% 23.30%
Employees 201 -
CDP Score - -

Address

12400 High Bluff Dr Ste 650
SAN DIEGO, CA 92130-3006
United States - Map
+1-858-2591165 (Phone)
+1-858-2591166 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Zogenix, Inc. (Zogenix) is a pharmaceutical company. The Company commercializes and develops products for the treatment of central nervous system disorders and pain. Its lead product candidate, Zohydro (hydrocodone bitartrate), an agonist, is used for the treatment of chronic pain requiring opioid therapy. The Company completed Phase III development of Zohydro in 2011. Zogenix�s second DosePro investigational product candidate, Relday, is an injectable formulation of risperidone for the treatment of schizophrenia. This trial was a randomized, 12-week, double-blind, placebo-controlled to evaluate the efficacy of Zohydro ER for the treatment of moderate to severe chronic lower back pain in opioid-experienced adult subjects. The Company also commercializes Sumavel DosePro, a needle-free delivery system. Sumavel DosePro offers the administration of sumatriptan for the acute treatment of migraine and cluster headache and is approved by the Food and Drug Administration (FDA).

Officers and directors

Cam L. Garner Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Stephen J. Farr Ph.D. President, Director
Age: 56
Bio & Compensation  - Reuters
Roger L. Hawley Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Ann D. Rhoads Chief Financial Officer, Executive Vice President, Treasurer, Secretary
Age: 49
Bio & Compensation  - Reuters
Bradley S. Galer M.D. Executive Vice President and Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
R. Scott Shively Executive Vice President, Chief Commercial Officer
Age: 57
Bio & Compensation  - Reuters
James B. Breitmeyer M.D., Ph.D. Director
Age: 60
Bio & Compensation  - Reuters
Renee P. Tannenbaum Director
Age: 62
Bio & Compensation  - Reuters
Louis C. Bock Independent Director
Age: 50
Bio & Compensation  - Reuters
Erle T. Mast Independent Director
Age: 51
Bio & Compensation  - Reuters